[go: up one dir, main page]

DK0614984T4 - Humane monoklonale anti-TNF-alfa-antistoffer - Google Patents

Humane monoklonale anti-TNF-alfa-antistoffer

Info

Publication number
DK0614984T4
DK0614984T4 DK94102560.3T DK94102560T DK0614984T4 DK 0614984 T4 DK0614984 T4 DK 0614984T4 DK 94102560 T DK94102560 T DK 94102560T DK 0614984 T4 DK0614984 T4 DK 0614984T4
Authority
DK
Denmark
Prior art keywords
tnf alpha
human monoclonal
human
monoclonal anti
alpha antibodies
Prior art date
Application number
DK94102560.3T
Other languages
English (en)
Other versions
DK0614984T3 (da
Inventor
Petra Boyle
Gayle D Wetzel
Kenneth J Lembach
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26701860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0614984(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of DK0614984T3 publication Critical patent/DK0614984T3/da
Publication of DK0614984T4 publication Critical patent/DK0614984T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
DK94102560.3T 1993-03-05 1994-02-21 Humane monoklonale anti-TNF-alfa-antistoffer DK0614984T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2695793A 1993-03-05 1993-03-05
US14506093A 1993-10-29 1993-10-29

Publications (2)

Publication Number Publication Date
DK0614984T3 DK0614984T3 (da) 2001-11-05
DK0614984T4 true DK0614984T4 (da) 2010-12-20

Family

ID=26701860

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94102560.3T DK0614984T4 (da) 1993-03-05 1994-02-21 Humane monoklonale anti-TNF-alfa-antistoffer

Country Status (11)

Country Link
US (1) US5654407A (da)
EP (1) EP0614984B2 (da)
JP (2) JP4225519B2 (da)
AT (1) ATE204299T1 (da)
CA (1) CA2116888C (da)
DE (2) DE69427928T3 (da)
DK (1) DK0614984T4 (da)
ES (1) ES2159529T5 (da)
LU (1) LU91661I2 (da)
NL (1) NL300421I2 (da)
PT (1) PT614984E (da)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU2013203420B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2013257402B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2012261708B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
JP4215172B2 (ja) * 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
CA2341276C (en) * 1998-08-28 2005-10-11 Genentech, Inc. Human anti-factor ix/ixa antibodies
PT1159003E (pt) * 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN1409639A (zh) * 1999-12-14 2003-04-09 杰南技术公司 应用TNF－α拮抗剂和LFA－1拮抗剂治疗LFA－1或TNF－α介导的疾病
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20090081234A1 (en) * 2000-08-07 2009-03-26 George Heavner Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20040185047A1 (en) * 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TWI556829B (zh) * 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2006092669A2 (en) * 2004-07-12 2006-09-08 Rappaport Family Institute For Research In The Medical Sciences Methods of detecting a phenotype of a polymorphic protein
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
DE602005026571D1 (de) * 2004-12-29 2011-04-07 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
RS52861B (sr) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
JP4861019B2 (ja) * 2006-01-31 2012-01-25 独立行政法人科学技術振興機構 ヒトＴＮＦ−αに対する抗体酵素およびその利用
TWI392684B (zh) 2006-04-05 2013-04-11 亞培生物科技公司 抗體之純化
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
AU2008205512B2 (en) * 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
WO2009032128A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
RU2537139C2 (ru) 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
US8883155B2 (en) * 2008-01-28 2014-11-11 The Regents Of The University Of California Methods for treating hematopoietic malignancies
KR20100135807A (ko) * 2008-03-13 2010-12-27 바이오테스트 아게 질병 치료제
EP2265643B1 (en) * 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
CN102027018A (zh) * 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
US8178092B2 (en) 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
WO2009148575A1 (en) * 2008-05-30 2009-12-10 Xbiotech, Inc. Interleukin-1 alpha abs and methods of use
EP2307457B2 (en) 2008-06-25 2022-06-22 Novartis AG Stable and soluble antibodies inhibiting tnf
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
WO2010034590A1 (en) * 2008-09-29 2010-04-01 Biotest Ag Composition for treating disease
US8415291B2 (en) * 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
CA2742791A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
JP2013504598A (ja) * 2009-09-14 2013-02-07 アボット・ラボラトリーズ 乾癬を治療するための方法
US8802826B2 (en) 2009-11-24 2014-08-12 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011091177A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
CN102167741B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
DK2582391T3 (da) 2010-06-18 2019-01-21 Xbiotech Inc Arthritis-behandling
WO2011163558A1 (en) 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
WO2012103260A2 (en) * 2011-01-25 2012-08-02 Cdi Laboratories High-throughput methods to produce, validate and characterize mmabs
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
EP2817028A4 (en) 2012-02-22 2015-11-04 Alethia Biotherapeutics Inc COMMON USE OF A CLUSTERIN INHIBITOR AND EGFR INHIBITOR FOR TREATING CANCER
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014151917A1 (en) 2013-03-14 2014-09-25 Ffe Therapeutics Llc Compositions and methods for treating angiogenesis-related disorders
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
EP3579871A4 (en) 2017-02-07 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
CN107903323B (zh) * 2017-11-15 2020-04-17 中国药科大学 抗hTNF-α全人源抗体及其用途
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
WO2020254861A1 (en) 2019-06-19 2020-12-24 Ovatrition Ltd. Antibody-mediated neutralization of beta-lactamases
WO2021234634A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2083688A (en) † 1987-07-09 1989-02-13 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Preparation of human monoclonal antibodies of selected specificity and isotypes
WO1991002756A1 (en) * 1989-08-16 1991-03-07 Cetus Corporation Prohormone cleavage site blocking antibody
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
GB9109645D0 (en) † 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DE69321909T2 (de) † 1992-08-28 1999-04-01 Bayer Corp., Pittsburgh, Pa. Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden

Also Published As

Publication number Publication date
EP0614984B2 (en) 2010-11-03
DE69427928T3 (de) 2012-05-10
US5654407A (en) 1997-08-05
ES2159529T3 (es) 2001-10-16
CA2116888C (en) 2003-08-12
JP2009046487A (ja) 2009-03-05
LU91661I2 (fr) 2010-05-10
JP4225519B2 (ja) 2009-02-18
EP0614984B1 (en) 2001-08-16
DE69427928D1 (de) 2001-09-20
DE69427928T2 (de) 2001-11-29
EP0614984A2 (en) 1994-09-14
ATE204299T1 (de) 2001-09-15
DE122009000074I1 (de) 2011-12-01
EP0614984A3 (en) 1995-05-24
NL300421I1 (nl) 2010-01-04
NL300421I2 (nl) 2010-04-01
JPH06319587A (ja) 1994-11-22
PT614984E (pt) 2001-12-28
ES2159529T5 (es) 2011-03-09
CA2116888A1 (en) 1994-09-06
DK0614984T3 (da) 2001-11-05

Similar Documents

Publication Publication Date Title
ATE204299T1 (de) Humane monoklonale anti-tnf alpha antikörper
IL83113A (en) Bifunctional antibodies having antigen specificity for fc receptor and for an epitope of a target cell
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
DK0848755T3 (da) VEGF relateret protein
FI834530L (fi) Affinitetsreningsfoerfarande medelst monoklonala anti-kroppar.
KR880700823A (ko) 사이토메갈로 바이러스에 대한 사람.모노클로날 항체와 그 제조방법
KR920006005A (ko) 인체 IgE에 대한 모노클론 항체
ATE375802T1 (de) Ccr5 antikörper pa14
Nasiri et al. Production and purification of polyclonal antibody against F (ab') 2 fragment of human immunoglobulin G
Bjerner et al. Human heterophilic antibodies display specificity for murine IgG subclasses
DE59410219D1 (de) Monoklonale antikörper gegen ck-mb
Weiss et al. Monoclonal antibodies to murine immunoglobulin isotypes
Kawashima et al. Antigenic Analyses of Sugi Basic Protein by Monoclonal Antibodies; I. Distribution and Characterization of B-Cell-Tropic Epitopes of Cry j I Molecules
Ohlson et al. High-performance liquid affinity chromatographic separation of mouse monoclonal antibodies with protein A silica
SE8201226L (sv) Antikroppar mot proteiner
Gerardo et al. Human IgG anti‐F (ab′) 2 antibodies possess rheumatoid factor activity
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
Würzner et al. Determination of the epitope specificities of monoclonal antibodies using unprocessed supernatants of hybridoma cultures
Alfa et al. Production of monoclonal antibodies against recombinant human interferon-gamma: Screening of hybridomas without purified antigen
Ćirić et al. Effect of valency on binding properties of the antihuman IgM monoclonal antibody 202
STUDIES Kazusuke Takeo, Ryosuke Suzuno, Masanori Fujimoto, Tatehiko
Stefanos et al. Characterization of antibodies against recombinant HuIFN-γ produced by hybridoma cells
McBride et al. Production and characterization of monoclonal antibodies directed against guinea pig IgG subclasses
Jones et al. The isotype and specificity of antiglobulins in BALB/c mice
Walker et al. Immunogenicity and antigenicity of immunoglobulins: detection of human immunoglobulin light-chain carbohydrate, using concanavalin A